Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Barcimiant vs Olumiant in Healthy Volunteers
NCT05006768Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA), alopecia areata and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started May 2021; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)alopecia areatacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05006768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006768.